XOMA

Insider Trades

Name	Value	Action	Price	Current Price
Hughes OwenDirector, Officer: Chief Executive Officer $2.5M100k shares BuyDec 4, 2025 $25.05 --
Burns Thomas M.SVP, Finance & CFO $55415 shares SellSep 22, 2025 $36.93 --
Burns Thomas M.SVP, Finance & CFO $55215 shares SellSep 22, 2025 $36.81 --
Burns Thomas M.SVP, Finance & CFO $155k4.3k shares SellSep 22, 2025 $35.98 --
Sitko BradleyChief Investment Officer $51k2k shares BuyJun 30, 2025 $25.39 --
Hughes OwenDirector, Officer: Chief Executive Officer $651k25.6k shares SellMay 20, 2025 $25.38 --

News

globenewswire.comXOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Dateglobenewswire.comJun 12

prnewswire.comAre AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders?prnewswire.comJun 12

globenewswire.comThe M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—TMHC, CZR, XOMA, and AVNSglobenewswire.comJun 11

seekingalpha.comSaying Goodbye To The XOMA Royalty PFDsseekingalpha.comMay 25

globenewswire.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)globenewswire.comMay 5

Trade XOMA

About XOMA Royalty Corp.

XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.

CEO: Owen Hughes Jr.
IPO Date: Jun 6, 1986

Market Data

Open: $41.90
High: $41.98
Low: $41.67
Volume: 86.3K
Avg Volume: 211K
52W High: $42.81
52W Low: $22.29

Valuation

Market Cap: $525M
Enterprise Value: $556M
Dividend Yield: 2.16%

Financials

Free Cash Flow: $2.9M
Revenue: $52M
Net Income: $32M
Cash: $83M
Debt: $132M

Events

EarningsAug 12

EPS est. 0.18